Global Innovation Hub

Choose Québec, a thriving environment for precision medicine Québec is a major hub for health biotech, fostering precision medicine innovation. Global leaders like Abbott, GSK, Medicago, Merck, Moderna, Novartis, and Sandoz operate here. The province offers affordable infrastructure, dedicated life sciences hubs, and low operating costs. Government support includes tax credits and investment funds. With 30,000 students in life sciences and 7,600 graduates yearly, Québec has a strong talent pool. Top universities excel in AI, bioinformatics, genomics, and immuno-oncology. The province also leads in biomarkers, diagnostics, gene therapy, and cell therapy. Cutting-edge research infrastructure strengthens its precision medicine ecosystem.

Seoul: Asia’s Strategic Bio & Clinical Innovation Hub Seoul is an emerging bio hub where clinical development, R&D, capital, and advanced manufacturing converge. The city hosts a dense ecosystem of over 1,200 biotech and life sciences companies, leading universities, and world-class hospitals, enabling strong collaboration and open innovation. With near-universal healthcare coverage, Seoul provides access to large-scale real-world data, supporting fast and efficient clinical research. Korea consistently ranks among the top countries globally in clinical trial activity, positioning Seoul as a leading clinical hub in Asia. Together, this integrated ecosystem makes Seoul a strategic gateway for biotech innovation and expansion across the Asia-Pacific region.

Sweden’s life science industry is a globally competitive and innovation-driven sector, spanning pharmaceuticals, biotechnology, medical technology, and digital health. Built on a strong foundation of academic excellence and public-private collaboration, the ecosystem connects leading universities, research institutes, healthcare providers, and companies of all sizes. Key hubs such as Stockholm-Uppsala, Gothenburg, and Medicon Valley foster entrepreneurship and attract international investment. With a focus on precision medicine, sustainability, and patient-centered care, Sweden continues to play a significant role in advancing global health.

Catalonia is a a Top European Hub in Scientific Excellence and R&D, ranking #1 in Horizon projects per capita and #4 in ERC grants, with the highest share of Highly Cited Papers. Its BioRegion hosts 1,650 companies, 94 research centres and 17 of the world’s top 20 pharma/medtech multinationals, and is Spain’s main pharmaceutical manufacturing hub with 79 plants. It is #7 worldwide and #4 in Europe in active clinical trials, participating in 92% of Spain’s studies, supported by hospitals excelling in advanced therapies and early‑phase research. In 2025, investment reached a record €517M, with 82% international VC, driven largely by biotech. Catalonia also offers exceptional talent, producing 26,000 STEM graduates annually, employing 18,500 researchers, and attracting 30+ new digital and health innovation hubs, including AstraZeneca’s €1.3B Global Hub in Barcelona, a major boost to the region’s innovation capacity.

France Biotech was founded in 1997 as an independent association, uniting the country’s leading innovative health companies and their expert partners. As a key facilitator of the health innovation ecosystem and a privileged point-of-contact for public authorities in France and Europe, France Biotech helps address the major challenges facing the HealthTech sector (including company financing, taxation, regulatory and market access issues, etc.). Its committees and working groups strive to identify viable solutions to create the necessary conditions for a competitive and attractive industry. Its objective is to support HealthTech startups and SMEs in becoming successful international companies capable of designing and developing innovative products and solutions rapidly and ultimately making them accessible to patients. France Biotech is the French equivalent of the US BIO (Biotechnology Innovation Organization). Lyonbiopôle is the health innovation cluster of the Auvergne-Rhône-Alpes region. It connects and supports industrial companies, SMEs, academic institutions, and healthcare stakeholders in the development of innovative solutions in biotech, medtech, and digital health. As a member of the national alliance of health clusters, Enosis Santé, Lyonbiopôle gives you access to some of the most dynamic health ecosystems and networks in France. Whether you work in oncology, neurology, or infectious diseases, or whether you are developing or manufacturing an ATMP, France offers high-level networks to help accelerate your innovation.

Queensland, Australia is a rapidly growing biomedical innovation hub and a strategic gateway to the Asia-Pacific region. Anchored by world-class research institutes, hospitals, and industry, the state delivers end-to-end capability from discovery to global impact: home to breakthroughs such as the Gardasil vaccine and innovations like The University of Queensland’s molecular clamp technology, now being advanced globally by companies such as ViceBio/Sanofi. Queensland features dedicated innovation hubs, advanced biomanufacturing infrastructure, and a globally competitive clinical trials environment. With strong collaboration, cost advantages, and access to diverse patient populations, it offers an ideal platform for developing and scaling biomedical innovations for global markets.

JBA is the largest and oldest biotechnology association in Japan, aiming to promote international open innovation and collaboration between Japan and the rest of the world.

Taiwan has targeted precision health, advanced manufacture, and digital health as its key elements for biomedical industry development. Besides a well-established infrastructure and various unique biomedical clusters, the government has launched regulations to promote new sectors of biomedical industry, such as cell therapies, digital health, and CDMO. This presentation will update the progress for the biomedical ecosystem in Taiwan, including incentives for advancing together with Taiwanese partners.

The Department for Business and Trade (DBT) is the UK Government department responsible for growing the economy through trade, investment, and business growth. DBT champions the UK as a leading global destination for life sciences innovation and investment. Working across government, industry, and the NHS, the department supports international companies looking to establish or expand operations in the UK, across R&D, clinical trials, manufacturing, and commercialization.

We will present an update from the Global Innovation Hub Switzerland including general trends in financing, partnering and international collaborations, and opportunities to liaise with the > 1500 Swiss biotech companies.

Invest in Italy: discover a vibrant Pharma & Biotech industry

The Netherlands offers a highly collaborative and innovation-driven Life Sciences & Health (LSH) ecosystem, positioning itself as a leading gateway to Europe’s Life Sciences & Health Metropolis. This presentation provides an overview of the Dutch LSH landscape, highlighting strong public-private partnerships, world-class research infrastructure, and a supportive regulatory and funding environment. With a dense network of innovative companies, top-tier knowledge institutions, and strategic government support, the Netherlands enables rapid translation from research to market. Attendees will gain insights into key strengths such as integrated health data systems, clinical trial readiness, and a focus on value-based healthcare. The session also explores opportunities for international collaboration, investment, and market entry, showcasing why the Netherlands is an attractive partner for global LSH stakeholders.

The Government of the State of Mexico will present its value proposition as a strategic hub for life sciences, highlighting its capabilities in pharmaceutical manufacturing, research, clinical development and investment attraction. As part of the MEXBIO Pavilion at BIO International Convention 2026, this presentation will showcase the State’s role in strengthening Mexico’s position within the global biotechnology ecosystem, aligned with national priorities such as Plan México. With a strong industrial base, skilled talent and proximity to one of the world’s largest healthcare markets, the State of Mexico offers opportunities for international collaboration across R&D, manufacturing and market access. The session aims to connect global partners with regional opportunities, fostering investment, innovation and cross-border partnerships in life sciences.

The CEO of the Andhra Pradesh Economic Development Board will present the state’s vision to emerge as a leading biomanufacturing hub in India. The session will highlight Andhra Pradesh’s rapidly evolving bioecosystem, with a focus on Visakhapatnam as a key growth centre supported by strong infrastructure, talent availability, and industry presence. The presentation will outline major upcoming initiatives, including the development of a Biotechnology Park and a state-of-the-art Quantum BioFoundry aimed at enabling next-generation bio-innovation and scale-up. It will also cover the state’s proactive policy framework designed to attract global investments, foster industry–academia collaboration, and support advanced biomanufacturing. Aligned with the Government of India’s BioE3 policy, Andhra Pradesh is positioning itself as a competitive destination for global life sciences companies seeking integrated ecosystems for research, development, and manufacturing.

The Department of Health – Abu Dhabi (DoH) is the regulator and strategic lead for Abu Dhabi's healthcare life-science (HLS) sector, and the stratgic lead of the HELM Cluster (an integrated platform spanning genomics, digital health, advanced therapies, clinical trials, and biomanufacturing). Abu Dhabi offers global partners a sovereign-backed environment combining the world's largest genomics program (900K+ genomes), nationally connected health data, accelerated regulatory pathways (8–15 day clinical trial approvals), strategic capital commitments to biotech infrastructure, and targeted incentive packages for R&D, manufacturing, and commercialization. Positioned as a neutral, competitive destination at the frontier of bioconvergence where genomics, AI, and clinical delivery converge at scale. Abu Dhabi is building the next global hub for healthcare life-science innovation and growth.